Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases
STANDARD DRUG DISCOVERY AND DEVELOPMENT
$1 to $2 billion
cost of developing a new drug
10 to 15 years
to develop a new drug
90%
of new chemical entities fail before they even reach the clinics
WE CAN REDUCE THOSE NUMBERS TO
$250k to $50M
cost of developing a new drug
4 to 5 years
to develop a new drug
OUR APPROACH
Leveraging the power of Artificial Intelligence
Focused on orphan diseases
Repurposing drugs for new therapeutic indications
PROPRIETARY PIPELINE
7 000
Only 5% have approved treatments
The main focus of our pipeline
are Orphan diseases with a
high unmet medical need.
Learn about our pipelinePARTNERSHIP
Workflow adapted to your needs.
Learn how you can work with usOur business model is a combination of in-house development and external collaborations. We have entered into multiple industry partnerships, as well as academic collaborations
OUR PERFORMANCE INDICATORS
77%
of our starting programs revealed positive hits that were confirmed at the laboratory bench and that were patentable
27%
of those hits are in preclinical or clincial development
20%
of those preclinical or clinical programs have clinical stage Phase 2 positive results
WE COOPERATE WITH
SOM BIOTECH IN THE MEDIA
LATEST NEWS
SOM Biotech signs licensing agreement with the University of Minnesota
SOM Biotech announced that it has signed a licensing agreement with the University of Minnesota. This license agreement follows the completion of research under a sponsored research agreement (SRA) signed in 2019, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular…
Rare Disease Day 2022
Today is Rare Disease Day 2022! At SOM Biotech we recognize the importance of raising awareness and progressing scientific research in the field of Rare Diseases. You can see our publications supporting rare Disease Day on LinkedIn and Twitter. Join us and get involved today: https://www.rarediseaseday.org/#.
SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority
SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a letter of intent with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, regarding a potential exclusive distribution agreement for the commercialization of SOM3355 to…
SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355
SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food…
SOM Biotech presents positive Phase 2a data with SOM3355 at the 34thECNP Congress 2021
Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile. SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO. SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of…
SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases
SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases. The course was held from the 5th to the 9th of July. Dr. Raúl Insa, CEO of the company, performed the presentation on the topic of drug repurposing for Rare Diseases. The main objective of the course was to…
